ArticleObesity surgery2026
Safety and Effectiveness of Metabolic and Bariatric Surgery Before and After Kidney Transplantation: A Systematic Review and Meta-Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundKidney transplantation is the optimal treatment for end-stage kidney disease. However, obesity limits access to and success of this procedure. While metabolic and bariatric surgery (MBS) can address obesity, its safety and effectiveness in transplant candidates and recipients have not been fully elucidated.
methodsThis systematic review and meta-analysis aimed to evaluate the safety and effectiveness of MBS performed in relation to kidney transplantation. Six databases were searched up to February 2, 2026. Randomized clinical trials and observational studies from any geographic region investigating MBS in adult kidney transplant candidates or recipients were included.
resultsA total of 49 studies (1504 patients) were included. For pre-transplant surgery (1215 patients), the pooled observed waitlisting rate was 78.0% (95% CI 66.0-88.0%; I²=90.3%; based on 26 studies comprising 719 patients), the observed transplantation rate was 52.0% (95% CI 36.0-68.0%; I²=96.3%; based on 32 studies comprising 1249 patients), and the 1-year graft survival rate was > 99% (95% CI 98%-100%; I²=17.5%; based on 11 studies comprising 232 patients). For post-transplant surgery (289 patients), the diabetes improvement rate was 93% (95% CI 64-100%; I²=21.4%; based on 4 studies comprising 52 patients) and the hypertension improvement rate was 92% (95% CI 54-100%; I²=52.7%; based on 3 studies comprising 38 patients) (defined as medication reduction/cessation or improvement in HbA1c/blood pressure). Waitlisting rates varied significantly by country (P < 0.001) but not by procedure type (P = 0.09). Formal tests did not detect small-study effects where assessable, but power was limited and selective outcome reporting remains possible. High heterogeneity limits generalizability.
conclusionIn selected patients with severe obesity, pre-transplant MBS was associated with transplantation access, and post-transplant surgery with metabolic improvement in small cohorts. Observed complication rates were acceptable, but controlled studies are needed. Because the evidence is predominantly observational and heterogeneous, comparative safety and long-term graft effects remain uncertain.
Indexed as
Identifiers
42560441What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.